Latest News
Masimo
Source Name: Masimo

Masimo India Introduces Low-Cost Pulse Oximetry

In an effort to make advanced medical technologies accessible to the masses, Masimo India to launch affordable healthcare solutions

Jan 07, 2015   15:55 IST 
Bangalore, Karnataka, India

Masimo Medical Technologies India Pvt. Ltd, a wholly owned subsidiary of Masimo (NASDAQ: MASI), a medical technology company known for its innovative noninvasive patient monitoring devices, today announced the launch of its low-cost pulse oximeter, the Sat 901+ for India.

 

Pulse oximetry is widely used and has gained critical importance in clinical care. Masimo has further revolutionised the world of pulse oximetry with its signal extraction technology (SET®), estimated to be used on more than 100 million patients a year in leading hospitals worldwide. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry is shown to virtually eliminate false alarms and help clinicians detect life-threatening events.1,2

 

Sat 901+ is designed for handheld and bedside monitoring, including acute care and alternate care settings such as long-term care facilities, homecare and sleep labs. This low-cost pulse-oximeter houses the same quality and patented SET® technology that allows clinicians to measure through motion and low perfusion. With the introduction of this new product, Masimo is well-positioned for the highly price-competitive market in India.

 

Medical device industry is innovating to design India-specific products to effectively cater to the unique needs of this market. Sat901+ has been designed to operate in a multitude of environments with extensive focus on portability and ease of use, both in urban and rural settings. “Masimo is committed to do what is best for patient care and believes that products like Sat901+ can help penetrate the rural healthcare market in India and bring patients in those areas the same advanced technologies that those in the cities benefit from. It is our goal to make technologies affordable and accessible,” said Bharat Monteiro, Country Manager - India &The Subcontinent, Masimo Medical Technologies India Pvt. Ltd.

 

Masimo is also trying to universalise screening for critical congenital heart disease (CCHD) in newborns across the county. Sat 901+ oximeter can definitely play a significant role in screening for CCHD, even in the remotest corners of India and help bring the infant mortality down. “We have been using Masimo technology for CCHD screening for several months now and have already made a difference in the lives of 3 babies who would not have been identified without the Masimo SET pulse-oximetry screen. I'm glad to see a low cost device from Masimo, this will make their superior SET technology more accessible to the rest of the departments within our hospitals," said Dr. Shalini Chico, Neonatologist, St. Martha’s Hospital, Bangalore.

 

Indian healthcare sector is in need of advanced medical technologies that will facilitate a more integrated healthcare system. Masimo’s noninvasive patient monitoring technologies are paving a way toward affordable and quality systems that will reduce errors and further augment the need for “patient-centric care.”

 

1 Shah N, Ragaswamy HB, Govindugari K, Estanol L "Performance of Three New-Generation Pulse Oximeters during Motion and Low Perfusion in Volunteers" .J ClinAnesth. 2012 Aug;24(5):385-91.


2 Taenzer, Andreas H.; Pyke, Joshua B.; McGrath, Susan P.; Blike, George T. "Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-and-After Concurrence Study." Anesthesiology, February 2010, Vol. 112, Issue 2.

 

About Masimo:
Masimo (NASDAQ: MASI) is the global leader in innovative noninvasive monitoring technologies that significantly improve patient care—helping solve "unsolvable" problems. In 1995, the company debuted Measure-Through Motion and Low Perfusion pulse oximetry, known as Masimo SET®, which virtually eliminated false alarms and increased pulse oximetry's ability to detect life-threatening events. More than 100 independent and objective studies have shown that MasimoSET®outperforms other pulse oximetry technologies, even under the most challenging clinical conditions, including patient motion and low peripheral perfusion. In 2005, Masimo introduced rainbow SET® Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously required invasive procedures, including total hemoglobin (SpHb®), oxygen content (SpOC™), carboxyhemoglobin (SpCO®), methemoglobin (SpMet®), and Pleth Variability Index (PVI®), in addition to SpO2, pulse rate, and perfusion index (PI). Additional information about Masimo and its products may be found at www.masimo.com.


Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including risks related to our assumptions of the repeatability of clinical results obtained, as well as other factors discussed in the "Risk Factors" section of our most recent reports filed with the Securities and Exchange Commission ("SEC"), which may be obtained for free at the SEC's website at www.sec.gov. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the "Risk Factors" contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.


Media Contact Details
Mike Drummond
Masimo Corporation
(949) 297-7434
Dileep M
Adfactors PR
+91 9742272204
Sujata Chakraborty
Adfactors PR
9916300645
 
 
For press background on Masimo

click here